Isis starts drug trials for anti-inflammatoryReports that Isis Pharmaceuticals Inc. has begun Phase II clinical trials of an anti-inflammatory drug, Isis 2302. Collaboration between Isis Pharmaceuticals I...
Attorney, Agent or Firm: Ionis Pharmaceuticals, Inc. (Carlsbad, CA, US) Parent Case Data: This application claims the benefit of U.S. Provisional Application No. 60/154,546 filed Sep. 17, 1999. Claims: What is claimed is: 1. An antisense compound 8 to 50 nucleobases in length targeted...
In 1998, the antisense compound, Vitravene® (fomivirsen; developed by Isis Pharmaceuticals Inc., Carlsbad, Calif.) was the first antisense drug to achieve marketing clearance from the U.S. Food and Drug Administration (FDA), and is currently a treatment of cytomegalovirus (CMV)-induced ...
Isis Lands $200M Lilly DealReports the investment of Eli Lilly & Co. on Isis Pharmaceuticals Inc. in Carlsbad, California. Amount of investment; Development of a drug for lung cancer; Market opportunity for non-small lung can...
Cheruvallath, Zacharia S. (San Diego, CA) Application Number: 09/481486 Publication Date: 06/05/2001 Filing Date: 01/11/2000 Export Citation: Click for automatic bibliography generation Assignee: Isis Pharmaceuticals, Inc. (Carlsbad, CA) ...
Isis Pharmaceuticals, Inc. United States Patent Application 20080311052 Kind Code: A1 Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of STAT 6 in a cell, tissue, or animal. Also provided are uses of disclosed compounds and compositions in the ...
Reports results in clinical trials of a drug to treat retinitis in AIDS patients by Isis Pharmaceuticals, Inc. Field of `antisense' drugs; Absence of effect on the HIV virus that causes AIDS; Need for confirmation of...
Isis Pharmaceuticals Inc. has announced that it has licensed a second-generation cancer drug candidate to its collaborator Eli Lilly and Co., triggering a $750,00 payment. Under the terms of the agreement, Lilly will...
Attorney, Agent or Firm: Ionis Pharmaceuticals, Inc. (Carlsbad, CA, US) Claims: 1. A compound comprising a plurality of linked nucleosides, wherein: each nucleoside includes a ribofuranosyl sugar portion and a base portion; and at least one of said nucleosides bears at a 2′-O-position or...
Methods for the regioselective alkylation at the 2′-hydroxy position over the 3′-hydroxy position of nucleosides and nucleoside analogs, forming 2′-O-ester modified compounds, are disclosed. Reduction and derivatization of the 2′-O-ester provides 2′-O-modified nucleosides and nucleoside analogs...